Bank of Montreal

Bank of Montreal has been paying uninterrupted dividends since 1829. The highlights of its business are its domestic retail & commercial bank and its wealth management unit. Its U.S. personal & business bank is a weak spot right now, partly due to elevated credit costs.» Mehr auf seekingalpha.com

Squarepoint Ops LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,009 shares of the company’s stock, valued at approximately $65,000. Squarepoint Ops LLC owned about 0.16% of Q32 Bio as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QTTB. Rhumbline Advisers grew its holdings in Q32 Bio by 1,164.3% during the fourth quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock worth $363,000 after acquiring an additional 97,196 shares during the period. Bleakley Financial Group LLC acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $149,000. Raymond James Financial Inc. acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $37,000. Cubist Systematic Strategies LLC purchased a new position in Q32 Bio during the fourth quarter worth about $42,000. Finally, Deutsche Bank AG lifted its position in Q32 Bio by 699.8% during the fourth quarter. Deutsche Bank AG now owns 25,018 shares of the company’s stock worth $86,000 after buying an additional 21,890 shares during the period. Hedge funds and other institutional investors own 31.32% of the company’s stock. Analyst Ratings Changes A number of equities analysts have recently commented on the company. Piper Sandler downgraded Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $4.00 in a report on Tuesday, February 11th. BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $22.00 to $3.00 in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut their price objective on Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.71. Read Our Latest Report on QTTB Q32 Bio Price Performance Shares of NASDAQ:QTTB opened at $1.68 on Wednesday. Q32 Bio Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $53.79. The business has a 50-day moving average of $1.75 and a two-hundred day moving average of $4.33. The stock has a market capitalization of $20.49 million, a P/E ratio of -0.12 and a beta of -0.03. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio (NASDAQ:QTTB – Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.33. On average, equities research analysts predict that Q32 Bio Inc. will post -12.32 EPS for the current fiscal year. Q32 Bio Company Profile (Free Report) Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. See Also Five stocks we like better than Q32 Bio Quiet Period Expirations Explained AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What is a Dividend Harvesting Strategy and How Can Investors Profit from it? Casey’s Surges on Strong Q4, More Gains Likely Ahead What is a Secondary Public Offering? What Investors Need to Know Government Mandate Sends eVTOL Stocks Flying» Mehr auf defenseworld.net

Not for distribution to U.S. news wire services or dissemination in the United States. PERTH, Australia, June 04, 2025 (GLOBE NEWSWIRE) -- FireFly Metals Ltd (ASX: FFM, TSX: FFM) (the “Company” or “FireFly”) has announced today that it has entered into an agreement with BMO Capital Markets, pursuant to which BMO Capital Markets has agreed to purchase, on a bought deal basis, 30,000,000 ordinary shares of the Company (the “Ordinary Shares”) at a price of C$0.86 (A$0.96) per Ordinary Share for gross proceeds of C$25.8 (approximately A$28.8)1 million (the “Canadian Offering”).» Mehr auf globenewswire.com